How to buy Recro Pharma stock | $1.74

Recro Pharma Inc is a drug manufacturers-specialty & generic business based in the US. Recro Pharma shares (REPH) are listed on the NASDAQ and all prices are listed in US Dollars. Recro Pharma employs 185 staff and has a trailing 12-month revenue of around 0.00.

Recro Pharma stock price (NASDAQ: REPH)

Use our graph to track the performance of REPH stocks over time.

Recro Pharma shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$1.74
52-week range	$1.49 - $5.29
50-day moving average	$2.04
200-day moving average	$2.27
Wall St. target price	$5.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.67

Buy Recro Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Recro Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Recro Pharma price performance over time

Historical closes compared with the close of $1.74 from 2021-10-25

1 week (2021-10-20)	1.74
1 month (2021-09-27)	-15.94%
3 months (2021-07-27)	-3.33%
6 months (2021-04-27)	-38.52%

1 year (2020-10-26)	-5.95%
2 years (2019-10-25)	-86.41%
3 years (2018-10-26)	6.57
5 years (2016-10-26)	7.15

Is Recro Pharma under- or over-valued?

Valuing Recro Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Recro Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Recro Pharma's EBITDA

Recro Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.2 million.

The EBITDA is a measure of a Recro Pharma's overall financial performance and is widely used to measure a its profitability.

Recro Pharma financials

Revenue TTM	$64 million
Gross profit TTM	$12.4 million
Return on assets TTM	-3.15%
Return on equity TTM	-351.19%
Profit margin	-30.18%
Book value	$0.57
Market capitalisation	$83.9 million

TTM: trailing 12 months

Shorting Recro Pharma shares

There are currently 676,092 Recro Pharma shares held short by investors – that's known as Recro Pharma's "short interest". This figure is 22.6% up from 551,539 last month.

There are a few different ways that this level of interest in shorting Recro Pharma shares can be evaluated.

Recro Pharma's "short interest ratio" (SIR)

Recro Pharma's "short interest ratio" (SIR) is the quantity of Recro Pharma shares currently shorted divided by the average quantity of Recro Pharma shares traded daily (recently around 263070.81712062). Recro Pharma's SIR currently stands at 2.57. In other words for every 100,000 Recro Pharma shares traded daily on the market, roughly 2570 shares are currently held short.

However Recro Pharma's short interest can also be evaluated against the total number of Recro Pharma shares, or, against the total number of tradable Recro Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Recro Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Recro Pharma shares in existence, roughly 10 shares are currently held short) or 0.0156% of the tradable shares (for every 100,000 tradable Recro Pharma shares, roughly 16 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Recro Pharma.

Find out more about how you can short Recro Pharma stock.

Recro Pharma share dividends

We're not expecting Recro Pharma to pay a dividend over the next 12 months.

Have Recro Pharma's shares ever split?

Recro Pharma's shares were split on a 1115:1000 basis on 21 November 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1115 shares. This wouldn't directly have changed the overall worth of your Recro Pharma shares – just the quantity. However, indirectly, the new 10.3% lower share price could have impacted the market appetite for Recro Pharma shares which in turn could have impacted Recro Pharma's share price.

Recro Pharma share price volatility

Over the last 12 months, Recro Pharma's shares have ranged in value from as little as $1.49 up to $5.29. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recro Pharma's is 1.1757. This would suggest that Recro Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Recro Pharma overview

Recro Pharma, Inc. , a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.

Frequently asked questions

What percentage of Recro Pharma is owned by insiders or institutions?
Currently 7.127% of Recro Pharma shares are held by insiders and 70.831% by institutions. How many people work for Recro Pharma?
Latest data suggests 185 work at Recro Pharma. When does the fiscal year end for Recro Pharma?
Recro Pharma's fiscal year ends in December. Where is Recro Pharma based?
Recro Pharma's address is: 1 E. Uwchlan Ave, Exton, PA, United States, 19341 What is Recro Pharma's ISIN number?
Recro Pharma's international securities identification number is: US75629F1093 What is Recro Pharma's CUSIP number?
Recro Pharma's Committee on Uniform Securities Identification Procedures number is: 75629F109